Home > Healthcare > Pharmaceuticals > Finished Drug Form > U.S. Viscosupplementation Market

U.S. Viscosupplementation Market Share

Report ID: GMI10692
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

U.S. Viscosupplementation Market Share

The competitive landscape of the market is characterized by a mix of established pharmaceutical companies and emerging players, each striving to capitalize on the growing demand for osteoarthritis treatments. Leading companies such as Anika Therapeutics, Inc., Sanofi SA, Ferring B.V., Bioventus, and Pacira BioSciences, Inc. hold significant market shares due to their extensive product portfolios and strong distribution networks. These companies leverage their research and development capabilities to innovate and introduce advanced formulations and delivery methods, aiming to enhance the efficacy and patient compliance of viscosupplementation therapies.

The market is also witnessing increased competition from smaller biotech firms and startups, which are focusing on niche segments and personalized treatment options. Strategic partnerships, mergers and acquisitions, and geographic expansion are common strategies adopted by these players to strengthen their market position and expand their customer base. The intense competition drives continuous improvements in product quality and cost-effectiveness, benefiting healthcare providers and patients alike.

U.S. Viscosupplementation Market Companies

Prominent players operating in the U.S. viscosupplementation industry include:

Anika Therapeutics, Inc
Avanos Medical, Inc
Bioventus Inc.
Ferring Pharmaceutical
Fidia Farmaceutici S.p.A (Fidia Pharma USA Inc.)
Lifecore Biomedical, Inc
Pacira BioSciences, Inc
Sanofi SA
Seikagaku Corporation
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

U.S. viscosupplementation market size was USD 1.1 billion in 2023 and is expected to register 7.6% CAGR from 2024-2032 owing to the rising prevalence of osteoarthritis, particularly in the aging population.

U.S. viscosupplementation industry from the 3 injections segment held 45.6% share in 2023 due to being supported by robust clinical evidence demonstrating its effectiveness in relieving symptoms of osteoarthritis and improving joint function.

U.S. viscosupplementation market from the non-avian segment is expected to reach USD 1.6 billion by 2032 due to reduced risk of allergic reactions, ethical and environmental considerations, and the assurance of consistency and purity with non-avian variety.

Bioventus Inc., Ferring Pharmaceutical, Fidia Farmaceutici S.p.A (Fidia Pharma USA Inc.), Lifecore Biomedical, Inc, Pacira BioSciences, Inc, Sanofi SA, Seikagaku Corporation, and Teva Pharmaceutical Industries Ltd., are some of the major viscosupplementation companies from the U.S.